• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (1)
    • An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
    • See All Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.

An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol Ther. 2003 May-Jun; 2(3):283-90.

View in: PubMed

subject areas
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Apoptosis
  • Apoptosis Regulatory Proteins
  • Blotting, Western
  • Caspases
  • Cell Division
  • Doxorubicin
  • Drug Resistance, Neoplasm
  • Epithelial Cells
  • Flow Cytometry
  • Humans
  • Ligands
  • Male
  • Membrane Glycoproteins
  • Prostate
  • Prostatic Neoplasms
  • Receptors, TNF-Related Apoptosis-Inducing Ligand
  • Receptors, Tumor Necrosis Factor
  • Stromal Cells
  • TNF-Related Apoptosis-Inducing Ligand
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha

authors with profiles
  • Christina Voelkel Johnson